EAMS

Black & Veatch Earns Highest Implementation Partnership with Leading Enterprise Asset Management System Provider, Trimble – Cityworks

Retrieved on: 
Tuesday, April 23, 2024
Technology, Construction & Property, Consulting, Engineering, Urban Planning, Professional Services, Software, Manufacturing, Data Management, Other Construction & Property, EAMS, Investment, GIS, LIMS, CCTV, SCADA, Partnership, Public works, Black, AMS, Recreation, Acquisition, Black & Veatch, Risk assessment, Platinum, Asset management

Global engineering, construction and consulting company Black & Veatch has earned platinum partnership status with Cityworks, a Trimble company.

Key Points: 
  • Global engineering, construction and consulting company Black & Veatch has earned platinum partnership status with Cityworks, a Trimble company.
  • As part of the enhanced partnership with Cityworks, Black & Veatch maintains its expertise with the platform to support clients as they build resilient, safe and sustainable communities using an enterprise asset management system (EAMS) with Esri GIS technology as the core asset repository.
  • Since 2014, Black & Veatch has partnered with Cityworks to offer clients a consolidated system of record for asset lifecycle management and improved decision-making that leverages client investments in enterprise GIS.
  • Cityworks software works to streamline public infrastructure management through its GIS-centric platform which includes work management, asset management, risk assessment, as well as tools for project permitting, licensing and land management.

KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat

Retrieved on: 
Tuesday, March 12, 2024
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, EAMS, Patient, HAE, National Health Service, Health care, NHS, American Academy, KALV, Expanded access, Marketing, MHRA, PIM, Hereditary angioedema, Safety, AAAAI, Pharmaceutical industry

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Promising Innovative Medicine (PIM) designation for sebetralstat, an investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE).

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Promising Innovative Medicine (PIM) designation for sebetralstat, an investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE).
  • The PIM is the first step in the Early Access to Medicines Scheme (EAMS) which would allow KalVista to treat patients with sebetralstat prior to receiving a Marketing Authorisation.
  • “We are proud to have sebetralstat designated as a Promising Innovative Medicine by the MHRA, which is similar to Expanded Access in the US,” said Ben Palleiko, Chief Executive Officer of KalVista.
  • KalVista recently provided phase 3 data for sebetralstat at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, which displayed clinically and statistically significant results across all endpoints, and an excellent safety and tolerability profile.

Dallas Area Rapid Transit Recognized as Best Maximo Implementation at the 2023 MaximoWorld Conference

Retrieved on: 
Tuesday, September 19, 2023
Cloud, SGR, ESRI, EAM, Workflow, Enterprise asset management, Smith, Transport, DART, EAMS, Mobile app, Lawson, Fleet management, Dallas Area Rapid Transit, Conference, Video game, Asset management, PHOENIX

PHOENIX, Ariz., Sept. 19, 2023 /PRNewswire-PRWeb/ -- Dallas Area Rapid Transit (DART) was awarded Best Maximo Implementation at the 2023 MaximoWorld Conference in Phoenix, AZ, for their work with Interloc Solutions, Inc. (Interloc) for their successful rollout of a fully mobilized, cloud-based Maximo solution incorporating all of DART's enterprise-wide assets. In his presentation at the events opening ceremonies, DART CIO Dr. Julius Smith, commented upon the enterprise rollout of Maximo across the DART enterprise, especially the impact to DART's mobile workforce. Smith also noted the 99.999% uptime over the past year as a testament to the reliability of the Interloc Cloud solution.

Key Points: 
  • Dallas Area Rapid Transit (DART) was awarded Best Maximo Implementation at the 2023 MaximoWorld Conference in Phoenix, AZ, for their work with Interloc Solutions, Inc. (Interloc) for their successful rollout of a fully mobilized, cloud-based Maximo solution incorporating all of DART's enterprise-wide assets.
  • PHOENIX, Ariz., Sept. 19, 2023 /PRNewswire-PRWeb/ -- Dallas Area Rapid Transit (DART) was awarded Best Maximo Implementation at the 2023 MaximoWorld Conference in Phoenix, AZ, for their work with Interloc Solutions, Inc. (Interloc) for their successful rollout of a fully mobilized, cloud-based Maximo solution incorporating all of DART's enterprise-wide assets.
  • In his presentation at the events opening ceremonies, DART CIO Dr. Julius Smith, commented upon the enterprise rollout of Maximo across the DART enterprise, especially the impact to DART's mobile workforce.
  • Smith also noted the 99.999% uptime over the past year as a testament to the reliability of the Interloc Cloud solution.

Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom

Retrieved on: 
Tuesday, August 15, 2023
Tissue, Salford Royal NHS Foundation Trust, National Health Service, Friends, Marketing, Health care, Glycogen, Medication, Glycogen storage disease type II, Amicus Therapeutics, EAMS, ERT, GAA, Patient, Trustee, Physician, Lysosome, National Institute for Health and Care Excellence, NHS, Rare, Enzyme replacement therapy, Therapy, Orphan, Family, PROPEL, NICE, MHRA, GB, Pharmaceutical industry, Cipaglucosidase alfa

PHILADELPHIA and MARLOW, United Kingdom, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (U.K.) has granted marketing authorizations for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) for adults living with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency). The indication for Pombiliti is a long-term enzyme replacement therapy (ERT) used in combination with miglustat for adults with late-onset Pompe disease (LOPD). The indication for Opfolda is an enzyme stabilizer of cipaglucosidase alfa long-term enzyme replacement therapy for adults with LOPD.

Key Points: 
  • The indication for Pombiliti is a long-term enzyme replacement therapy (ERT) used in combination with miglustat for adults with late-onset Pompe disease (LOPD).
  • The indication for Opfolda is an enzyme stabilizer of cipaglucosidase alfa long-term enzyme replacement therapy for adults with LOPD.
  • Disease severity ranges on a spectrum, but predominant manifestations are skeletal muscle weakness and progressive respiratory involvement.
  • Both will benefit from 10 years of market exclusivity in respect of similar medicinal products in the approved orphan indication.

Revolutionizing Water Sector: Aquasight's AMP™ Transforms Traditional Asset Management

Retrieved on: 
Thursday, July 20, 2023
AWWA, Workforce, Ageing, EAMS, ROI, SRF, Algorithm, Water, GIS, Asset management

TROY, Mich., July 20, 2023 /PRNewswire/ -- Aquasight Intelligent Water Solutions unveils its groundbreaking upgrades to AMP™, a cloud-based asset management plan designed to address the sector's most pressing issue - aging water infrastructure. Traditional asset management approaches are falling short in providing continuous updates, real-time risk analysis, and streamlined virtual team collaboration, as highlighted by a recent AWWA survey. Aquasight's AMP™ bridges this gap by revolutionizing asset management through intelligent algorithms and advanced functionalities.

Key Points: 
  • Traditional asset management approaches are falling short in providing continuous updates, real-time risk analysis, and streamlined virtual team collaboration, as highlighted by a recent AWWA survey.
  • Aquasight's AMP™ bridges this gap by revolutionizing asset management through intelligent algorithms and advanced functionalities.
  • Aquasight's AMP™ brings asset management into the digital age by combining familiar spreadsheet and GIS-based functionalities with intelligent algorithms.
  • AMP™ differentiates itself from existing Enterprise Asset Management Systems (EAMS) with its robust GIS-based asset risk and capital planning features.

TMA Systems Welcomes Ed Roshitsh to Board of Directors

Retrieved on: 
Tuesday, July 18, 2023
Data Management, Professional Services, Technology, Asset Management, Software, Software as a service, Computerized maintenance management system, Heroes, EAMS, Pleasure, InteLex Past Masters, Growth, CMMS, TMA, Management, Holiday, Blackbaud, Brightly

TMA Systems , a US-based leader and developer of Computerized Maintenance Management Systems (CMMS) and Enterprise Asset Management Solutions (EAMS), today announced the appointment of Ed Roshitsh to the Company’s Board of Directors.

Key Points: 
  • TMA Systems , a US-based leader and developer of Computerized Maintenance Management Systems (CMMS) and Enterprise Asset Management Solutions (EAMS), today announced the appointment of Ed Roshitsh to the Company’s Board of Directors.
  • As the company’s first independent board director, Roshitsh will leverage his deep experience in the enterprise SaaS market to support TMA Systems’ future growth initiatives.
  • “Ed is an ideal addition to our Board of Directors,” said Mark Simner, Chief Executive Officer at TMA Systems.
  • “We are thrilled to welcome him to the Board of Directors at TMA Systems.

Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates

Retrieved on: 
Wednesday, May 10, 2023
Fabry, Loss, Table, Civil service commission, CER, CER1, European Directive on Traditional Herbal Medicinal Products, Amicus, Glycogen storage disease type II, GAAP, Committee, PIN, EAMS, Acquisition, Patient, Physician, Cipaglucosidase alfa, European, Growth, WuXi Biologics, Depreciation, Diagnosis, Committee for Medicinal Products for Human Use, Orange Book, Amicus Therapeutics, FDA, Therapy, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, European Commission, Wuxi, CHMP, Pharmaceutical industry, Bank, Video game, Cryptocurrency, EU, Migalastat

In the U.K., the regulatory submission process was initiated in December 2022, with final approval expected in the third quarter of 2023.

Key Points: 
  • In the U.K., the regulatory submission process was initiated in December 2022, with final approval expected in the third quarter of 2023.
  • Total GAAP operating expenses of $117.0 million for the first quarter 2023 decreased as compared to $146.5 million for the first quarter 2022.
  • ET to discuss the first quarter 2023 financial results and corporate updates.
  • A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com .

Embraer and EmpowerMX Partner to Solve On-the-Job Training Constraints

Retrieved on: 
Wednesday, April 26, 2023
Aircraft, Maintenance, Digital, OJT, EAMS, Record, MRO, Embraer, Maintenance (technical), Asset management

FRISCO, Texas, April 26, 2023 /PRNewswire-PRWeb/ -- EmpowerMX, the leading cloud-based Digital MRO solutions provider, today announced a successful launch of their partnered on-the-job (OJT) initiative with Embraer Aircraft Maintenance Services (EAMS), the world's leading provider of heavy maintenance for Embraer commercial jets. By switching to the EmpowerMX system, EAMS was able to eliminate paper and improve visibility due to more timely and accurate records.

Key Points: 
  • EmpowerMX cloud-first MRO Manager delivers additional capabilities for Embraer employees to log their records directly from the tasks they are performing.
  • This allows technicians to easily record training in a system they are natively using every day.
  • By switching to the EmpowerMX system, EAMS was able to eliminate paper and improve visibility due to more timely and accurate records.
  • This allows technicians to easily record training in a system they are natively using every day," said Jason Grafton , Managing Director of Embraer Aircraft Maintenance Services.

Santhera Submits Marketing Authorization Application to the UK MHRA for Vamorolone in Duchenne Muscular Dystrophy

Retrieved on: 
Thursday, March 2, 2023
Safety, Orphan drug, FDA, European Medicines Agency, Vamorolone, MAA, Health care, NDA, Maintenance, Duchenne muscular dystrophy, Patient, CMO, PDUFA, Food and Drug Administration Amendments Act of 2007, DMD, EMA, Prednisone, MHRA, PIM, Food, Prescription Drug User Fee Act, EAMS, Pharmaceutical industry, MD, EU

Pratteln, Switzerland, March 2, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces that it has submitted a marketing authorization application (MAA) to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for vamorolone for the treatment of Duchenne muscular dystrophy (DMD).

Key Points: 
  • Pratteln, Switzerland, March 2, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces that it has submitted a marketing authorization application (MAA) to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for vamorolone for the treatment of Duchenne muscular dystrophy (DMD).
  • In parallel to the MAA submission to the UK MHRA, Santhera is currently preparing an application to include vamorolone for the treatment of DMD in the Early Access to Medicines Scheme (EAMS) in the UK.
  • “We are proud to have completed the third submission for vamorolone in DMD to a major regulatory agency within a few months.
  • Subject to approvals, Santhera plans to launch vamorolone in both the U.S. and the EU in Q4-2023.

Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates

Retrieved on: 
Wednesday, March 1, 2023
CHMP, Glycogen storage disease type II, Safety, Depreciation, Therapy, Amicus, Diagnosis, Amicus Therapeutics, Growth, Committee, CER1, Committee for Medicinal Products for Human Use, GAAP, Acquisition, EAMS, FDA, Patient, Fabry disease, CER, Table, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Loss, PIN, European Directive on Traditional Herbal Medicinal Products, Food, Physician, Pharmaceutical industry, Cryptocurrency, Bank, Migalastat, Fabry, EU

The regulatory submission process for AT-GAA in the U.K. was initiated in December 2022, with final approval expected in the third quarter of 2023.

Key Points: 
  • The regulatory submission process for AT-GAA in the U.K. was initiated in December 2022, with final approval expected in the third quarter of 2023.
  • Amicus Therapeutics will host a conference call and audio webcast today, March 1, 2023 at 8:30 a.m.
  • ET to discuss the full-year 2022 financial results and corporate updates.
  • A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com .